The gene for von Recklinghausen neurofibromatosis (NF 1) was recently identified by positional cloning and found to code for a large, ubiquitously expressed protein. This protein has both structural and functional similarity to a family of proteins with guanosine triphosphatase-activating properties, involved in the regulation of the protooncogene ras. One of the postulated functions of the NFI gene product may relate to its ability to regulate ras-mediated cell proliferation. Selective pharmacotherapy directed at downregulating ras may be of benefit to patients with NF1. In fact, the phenotype of disease in patients with deletions of OMgp, EVI2A, and EVI2B is the same as that of patients with point mutations in the NFI gene C4-61, indicating that the embedded genes may not affect the usual manifestations of the disease. Two of these genes, EVI2A and EVI2B, are human homologues of putative mouse protooncogenes that may play a role.in the pathogenesis of murine myeloid tumors. Juvenile chronic myelogenous leukemias have keen reported to occur more frequently in NF1 patients than in the general population, suggesting a possible role for these genes in NF1-related myeloid malignancies {2]. However, thus far, there is no evidence for mutations in these genes in NF1 patients or significant differences in the abundance of EVI2A and EVI2B mRNA in NF1 patients. Of additional interest is the OMgp gene, encoding an abundant myelin protein (oligodendrocyte-myelin glycoprotein), which was previously thought to be a good candidate for the NFI gene, given its role in central nervous system cell-cell communication E l 11. Again, there is no evidence to directly implicate the OMgp gene in the pathogenesis of NFI.
Neurofibromatosis type 1 (NFl), or von Recklinghausen neurofibromatosis, is one of the most common autosomal dominant disorders in humans. It is characterized by abnormalities affecting tissues derived primarily, but not exclusively, from the neural crest, including multiple neurofibromas, cafe-au-lait spots, axillary freckling, Lisch nodules of the iris, distinct bony lesions, and optic nerve gliomas [l] . The NFI locus is unusual in that the spontaneous mutation rate is estimated to be 100-fold higher than the usual rate for a single locus; 30 to 50% of cases represent new mutations [ 11. The risk of malignancy is also increased, especially for neurofibrosarcomas and brain tumors c21.
Early linkage analysis demonstrated that the locus for NF2 resides on chromosome 17 131. The identification of two patients with chromosome 17 translocations facilitated the identification of the gene for NFI . Further chromosomal and cDNA walking culminated in the determination of the entire NFl coding sequence C7f.
The NFl Gene The gene for NFI spans approximately 300 kb of genomic DNA and encodes an approximately 13-kb messenger RNA with an open reading frame of 8,454 nucleotides [7] (Fig 1) . The predicted protein product is 2,818 amino acids with a predicted molecular mass of 327 kd 171. Forty-nine exons and two alternatively spliced mRNA isoforms have been identified. An unexpected finding was the discovery of three genes embedded within one intron of the NFI gene. These three genes, OMgp {S), EVI2A [9}, and EVI2B {lo] , are transcribed in the opposite orientation as the NFI gene and their contribution to the disease is uncertain.
In fact, the phenotype of disease in patients with deletions of OMgp, EVI2A, and EVI2B is the same as that of patients with point mutations in the NFI gene C4-61, indicating that the embedded genes may not affect the usual manifestations of the disease. Two of these genes, EVI2A and EVI2B, are human homologues of putative mouse protooncogenes that may play a role.in the pathogenesis of murine myeloid tumors. Juvenile chronic myelogenous leukemias have keen reported to occur more frequently in NF1 patients than in the general population, suggesting a possible role for these genes in NF1-related myeloid malignancies {2]. However, thus far, there is no evidence for mutations in these genes in NF1 patients or significant differences in the abundance of EVI2A and EVI2B mRNA in NF1 patients. Of additional interest is the OMgp gene, encoding an abundant myelin protein (oligodendrocyte-myelin glycoprotein), which was previously thought to be a good candidate for the NFI gene, given its role in central nervous system cell-cell communication E l 11. Again, there is no evidence to directly implicate the OMgp gene in the pathogenesis of NFI.
The mRNA for NFI is ubiquitously expressed, suggesting that the neural crest predominance of abnor- (arrow) Collins FS, and Downward J, unpublished data). 1Jsing antibodies generated against fusion proteins and synthetic peptides, a unique 250-kd protein was found in all tissues and cell lines examined ([207; Fig 2) . Immu-. noblot analysis of adult mouse tissues demonstrated the highest levels of expression in brain, kidney, and spleen 120). The difference between the predicted1 molecular mass (327 kd) and the observed size (250 kd) is most likely due to anomalous migration and not to protein processing (Gutmann DH, unpublishe'd results) . This protein was localized to the cytoplasm by two different methods, differential centrifugation (Basu TN, Gutmann D H , Collins FS, and Downward J, unpublished data) and glycerol gradients [2 11. Indi-. rect immunoff uorescence using antibodies generated against neurofibromin likewise demonstrated cytoplasmic localization (Gregory PE, Gutmann DH, Boguski M, Wood DL, and Collins FS, unpublished data). Neurofibromin appears to colocalize with microtubules in all cell types examined by imrnunofluorescence and biochemical purification, suggesting that neurofibromin is intimately associated with cytoskeletal elements (Fig 3) .
Function of Neurofibromin
Undifferentiated cells contain the genetic capacity for rapid growth during embryonic development as .well as differentiation into specific tissues. In addition to genes that facilitate growth and differentiation (protooncogenes), cells also contain genes that code for proteins that inhibit these processes. The genes that downregulate the expression of growth-promoting factors are termed tumor suppressor genes 1221. Progression to malignancy, or transformation, can therefore arise as a result of activating mutations in genes that facilitate cell growth (e.g., protooncogenes) or inactivating mutations in genes that inhibit these processes (tumor suppressor genes). Evidence for the existence of these tumor suppressor genes is based in part on the genetic predisposition of certain individuals to some pediatric malignancies; fusion of normal cells with certain pediatric tumor cells leads to suppression of the tumorigenic phenotype and chromosomal loss often accompanies the return to the neoplastic state. Tumor formation or transformation occurs when these genes are inactiTumor Suppressor Genes vated, implying that their normal function is to limit cell proliferation. This mechanism, originally known as the Knudson hypothesis, has been most thoroughly demonstrated for the retinoblastoma gene 1231. The known tumor suppressor genes are listed in the Table. In an inherited cancer syndrome, like NF1, each somatic cell in an affected individual has one normal copy of the NFI gene; the other copy is inherited as a mutant gene. However, in the abnormal neural crest tissues, the one remaining normal NFI gene is hypothesized to undergo somatic mutation to render both copies nonfunctional (C231; Fig 4) . The ras-GTP levels and reduced neurofibromin expression, perhaps as a result of mutations in the NFI gene in these cells [26] .
In normal cells the role of neurofibromin has not been established. GAP, the mammalian GTPase m ivating protein, is phosphorylated on tyrosine residues in response to growth factor stimulation and becomes associated with other signal transduction proteins 127).
This tyrosine phosphorylation event inactivates GAP, resulting in increased ras-GTP levels bromin, on the other hand, is phosphorylated on serine and threonine residues in response to growth factor stimulation and may become inactivated in an analogous manner to G A P (Basu TN, Gutmann DH, Collins FS, and Downward J, unpublished data). Based on the similarity to GAP, neurofibromin can be postulated to downregulate ras in the absence of growth factor stimulation but is inactivated in response to growth factors as part of a signal transduction pathway leading to ras activation and cell proliferation (see Fig 5) .
The apparent ubiquitous expression of the NFI protein represents a contrast to the predominance of neural crest involvement in this disease. Recent evidence suggests that neurofibromin is expressed predominantly in brain, kidney, and spleen with detectable levels in white blood cells (D. H. Gutmann, unpublished data unpublished results). Possibly, the tissue specificity ot this disease may reflect an association between the N F I protein and other cellular signal transduction molecules that are expressed predominantly in tissues derived from neural crest.
Mutations in Patients with N F l
Examination of patients with NF1 by DNA, RNA, and protein analysis is still in its infancy. To date, the following two types of mutations have been described in NF1 patients: (1) large megabase deletions in patients with NF1 and mental retardation and (2) smaller kilobase deletions, translocations, and microalterations.
Large deletions involving huge stretches of DNA including the entire NFI locus have been described in patients with "classic" NF1 and significant mental retardation C291. These deletions probably eliminate other genes involved in central nervous system development in addition to the NFI gene to account for the mental retardation. Smaller deletions and translocations interrupting the NFI gene have been reported (f4, 61, Wallace M, unpublished results; Legius E, unpublished results). One patient with a single nucleotide mutation creating a stop codon and presumably an abnormal protein has been described 161. Preliminary studies examining fibroblast and white blood cell lines from NF1 patients have thus far failed to detect abnormally migrating neurofibromin proteins (Gutmann DH, unpub- lished data), as was reported for dystrophin in Duchenne and Becker muscular dystrophy patients [ 3 0 ] . At this time, there is no clear correlation between the site of the NFI mutation and the clinical phenotype; in fact, there is not expected to be much phenotypegenotype correlation because of the great variability in phenotype within NF1 families.
Future Directions The Role of NF1 as a Tumor Supprrs8or Gme
There is still much to learn about neurohbromin anti its role in tumor biology, cell growth, and development. One function of a small portion of neurofibromin (10% of the entire molecule) has been delineated, but it remains to be proved that the entire neurofibromin molecule can downregulate rat. What GAP to direct cytoarchitectural changes in the cell in response to growth factors. If neurofibromin is analogous to GAP, in that phosphorylation downregulates its activity [28) , then inhibition of neurofibromin's role in limiting cell proliferation through either ru.r and/or some interaction with microtubule elements could be envisioned to result in unlimited cell growth or transformation.
NFl Animal Models
Much effort is being invested in several laboratories to create a mouse model for NF1 by creating a germline knockout of the NFl gene, and the resulting phenotype will be of considerable interest. Previously, transgenic mice generated by introducing the human T-lymphotropic virus type 1 (HTLV-I) 
lbhrrupy
The cloning of the NFI gene opens the door to a more complete understanding of N F 1 pathobiology with the goal of designing specific, nonsurgical treatments for affected patients. The finding of elevated m.$-GTP levels in tumors from NF1 patients suggests that the inability of neurofibromin to downregulate may have something to do with the development of neurofibromas. Ru. 1 is normally found in the cytoplasm but becomes membrane associated after the addition of a farnesyl lipid group tfarnesylation). Oncc associated with the membrane, ya.i participates in events that culminate in transformation. Drugs that inhibit farnesylation have been shown to inhibit the mitogenic effects of growth factors and the tumorigenic properties of neuroblastoma cells (reviewed in 137)j. More useful therapies might involve drugs thar inhibit farnesyl transferase (addition of farnesyl group to the m.r protein,, rather than lovastatin and cornpactin, which block farnesyl synthesis. Further study of these and related drugs may provide useful therapies for NFI patients. 
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